Solvay Pharma
Solvay Pharma, a prominent division of Solvay Group, is headquartered in France and operates extensively across Europe, North America, and Asia. Established in 1995, the company has made significant strides in the pharmaceutical industry, focusing on innovative treatments in areas such as central nervous system disorders, women's health, and rare diseases. Renowned for its commitment to research and development, Solvay Pharma offers a range of unique products that address unmet medical needs, setting it apart in a competitive market. With a strong emphasis on sustainability and patient-centric solutions, the company has achieved notable recognition for its contributions to healthcare. As a key player in the pharmaceutical landscape, Solvay Pharma continues to advance its mission of improving patient outcomes through cutting-edge therapies.
DitchCarbon Score
How does Solvay Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Solvay Pharma's score of 28 is higher than 50% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Solvay Pharma's reported carbon emissions
In 2018, Solvay Pharma reported total carbon emissions of approximately 14,250 kg CO2e, comprising 10,350 kg CO2e from Scope 1, 1,900 kg CO2e from Scope 2, and 1,900 kg CO2e from Scope 3 investments. Other significant contributions to Scope 3 emissions included 5,800 kg CO2e from purchased goods and services, 700 kg CO2e from fuel and energy-related activities, 800 kg CO2e from downstream transportation and distribution, and 20 kg CO2e from business travel. Comparatively, in 2017, the total emissions were about 14,900 kg CO2e, with Scope 1 emissions at 10,200 kg CO2e, Scope 2 at 2,100 kg CO2e, and Scope 3 emissions including 1,700 kg CO2e from investments and 6,600 kg CO2e from purchased goods and services. Despite these figures, Solvay Pharma has not publicly disclosed specific reduction targets or initiatives under the Science Based Targets initiative (SBTi) or other climate pledges. The company continues to monitor and report its emissions across all scopes, demonstrating a commitment to transparency in its climate impact.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2015 | 2016 | 2017 | 2018 | |
|---|---|---|---|---|
| Scope 1 | 11,400 | 00,000 | 00,000 | 00,000 |
| Scope 2 | 2,800 | 0,000 | 0,000 | 0,000 |
| Scope 3 | 11,920 | 00,000 | 0,000 | 0,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Solvay Pharma is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
